ArticleSurgery today2026
Safety and efficacy of tolvaptan sodium phosphate in patients undergoing open-heart surgery.
Article in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposesTolvaptan sodium phosphate (TSP) is an intravenous aquaretic agent that is rapidly converted to tolvaptan after administration. This study aimed to evaluate the safety and efficacy of TSP in open-heart surgery cases.
methodsThis study included 103 patients (31 women; mean age, 70.5 ± 10.8 years) who received intravenous TSP following open-heart surgery. The urine output was measured hourly from 1 h before to 6 h after administration, and time-dependent changes were assessed. The magnitude of the response was defined as ΔU1-6 = (U1+U2+U3+U4+U5+U6) - U-1. Patients were ranked according to ΔU1-6, and the top 25 (marked responders) and bottom 25 (poor responders) were compared.
resultsThe urine output was significantly increased within 1-3 h after TSP administration, peaked at 2-3 h, and remained above the baseline through 6 h (all p < 0.05). In a multivariable linear regression analysis, the serum sodium level at the time of TSP administration was independently associated with ΔU1-6 (p=0.018). The serum sodium levels at TSP administration were lower in marked responders (p=0.033). No TSP-related adverse events were observed in any of the cases.
conclusionsIntravenous TSP can induce a rapid and sustained diuretic response following open-heart surgery, and the serum sodium levels determine the magnitude of the aquaretic response to intravenous TSP.
Indexed as
Identifiers
42678407What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.